Fenglong Bie
Overview
Explore the profile of Fenglong Bie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yue P, Bie F, Zhu J, Gao L, Zhou Z, Bai G, et al.
Mol Cancer
. 2024 May;
23(1):96.
PMID: 38730415
Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality of life for cancer patients. We developed a minimal residual...
2.
Bai G, Chen X, Peng Y, Ji Y, Bie F, Liu Y, et al.
Thorac Cancer
. 2024 Apr;
15(14):1138-1148.
PMID: 38572774
Background: In China, real-world data on surgical challenges and postoperative complications after neoadjuvant immunotherapy of lung cancer are limited. Methods: Patients were retrospectively enrolled from January 2018 to January 2023,...
3.
Liu Y, Bie F, Bai G, Huai Q, Li Y, Chen X, et al.
Clin Transl Oncol
. 2024 Apr;
26(8):2025-2036.
PMID: 38563846
Background: Neoadjuvant immunotherapy has evolved as an effective option to treat non-small cell lung cancer (NSCLC). B cells play essential roles in the immune system as well as cancer progression....
4.
Guo W, Zhou B, Bie F, Huai Q, Xue X, Guo L, et al.
Clin Transl Med
. 2023 Oct;
13(10):e1453.
PMID: 37846760
Introduction: With the advancements in early diagnosis, more and more patients with multiple primary lung cancer (MPLC) have been identified. However, the progression of MPLC involves complex changes in cell...
5.
Bie F, Wang Z, Li Y, Guo W, Hong Y, Han T, et al.
Nat Commun
. 2023 Sep;
14(1):6042.
PMID: 37758728
Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we...
6.
Huai Q, Luo C, Song P, Bie F, Bai G, Li Y, et al.
Cancer Sci
. 2023 Sep;
114(12):4484-4498.
PMID: 37731264
Neoadjuvant immunotherapy has significantly changed the therapeutic approach for treating patients with surgically resectable non-small cell lung cancer (NSCLC). Here, peripheral blood inflammation-based biomarkers as well as previously less focused...
7.
Chen X, Bai G, Zang R, Song P, Bie F, Huai Q, et al.
Transl Oncol
. 2023 Jul;
35:101725.
PMID: 37421908
Purpose: The aim of present study was to investigate the efficiency of F-FDG uptake in predicting major pathological response (MPR) in resectable non-small cell lung cancer (NSCLC) patients with neoadjuvant...
8.
Ma G, Zeng Y, Zhong W, Zhao X, Wang G, Bie F, et al.
Exp Ther Med
. 2023 Jul;
26(2):370.
PMID: 37415839
Suppressor of cytokine signaling 2 (SOCS2) plays an essential role in a number of physiological phenomena and functions as a tumor suppressor. Understanding the predictive effects of SOCS2 on non-small...
9.
Li Y, Zhou A, Liu S, He M, Chen K, Tian Z, et al.
BMC Med
. 2023 Mar;
21(1):86.
PMID: 36882775
Background: A Phase II study was undertaken to evaluate the safety and efficacy of the neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel and cisplatin for locally advanced...
10.
Zhou B, Zang R, Song P, Zhang M, Bie F, Bai G, et al.
J Transl Med
. 2023 Jan;
21(1):10.
PMID: 36624443
Background: The most common form of treatment for non-metastatic lung cancer is surgery-based combination therapy, which may also include adjuvant radiotherapy or chemotherapy. Second primary malignancies (SPMs) are uncommon but...